Skip to Content
Merck
CN

Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopenia.

Nature communications (2018-10-14)
Sharissa L Latham, Nadja Ehmke, Patrick Y A Reinke, Manuel H Taft, Dorothee Eicke, Theresia Reindl, Werner Stenzel, Michael J Lyons, Michael J Friez, Jennifer A Lee, Ramona Hecker, Michael C Frühwald, Kerstin Becker, Teresa M Neuhann, Denise Horn, Evelin Schrock, Indra Niehaus, Katharina Sarnow, Konrad Grützmann, Luzie Gawehn, Barbara Klink, Andreas Rump, Christine Chaponnier, Constanca Figueiredo, Ralf Knöfler, Dietmar J Manstein, Nataliya Di Donato
ABSTRACT

Germline mutations in the ubiquitously expressed ACTB, which encodes β-cytoplasmic actin (CYA), are almost exclusively associated with Baraitser-Winter Cerebrofrontofacial syndrome (BWCFF). Here, we report six patients with previously undescribed heterozygous variants clustered in the 3'-coding region of ACTB. Patients present with clinical features distinct from BWCFF, including mild developmental disability, microcephaly, and thrombocytopenia with platelet anisotropy. Using patient-derived fibroblasts, we demonstrate cohort specific changes to β-CYA filament populations, which include the enhanced recruitment of thrombocytopenia-associated actin binding proteins (ABPs). These perturbed interactions are supported by in silico modeling and are validated in disease-relevant thrombocytes. Co-examination of actin and microtubule cytoskeleton constituents in patient-derived megakaryocytes and thrombocytes indicates that these β-CYA mutations inhibit the final stages of platelet maturation by compromising microtubule organization. Our results define an ACTB-associated clinical syndrome with a distinct genotype-phenotype correlation and delineate molecular mechanisms underlying thrombocytopenia in this patient cohort.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Tropomyosin 4 Antibody, serum, Chemicon®